These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 27680685)

  • 21. Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area.
    Heeren AM; de Boer E; Bleeker MC; Musters RJ; Buist MR; Kenter GG; de Gruijl TD; Jordanova ES
    Oncotarget; 2015 Oct; 6(32):32484-93. PubMed ID: 26431490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunosuppressive drugs on inducing Ag-specific CD4(+)CD25(+)Foxp3(+) Treg cells during immune response in vivo.
    Wu T; Zhang L; Xu K; Sun C; Lei T; Peng J; Liu G; Wang R; Zhao Y
    Transpl Immunol; 2012 Aug; 27(1):30-8. PubMed ID: 22613676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma.
    Schneider T; Kimpfler S; Warth A; Schnabel PA; Dienemann H; Schadendorf D; Hoffmann H; Umansky V
    J Thorac Oncol; 2011 Mar; 6(3):432-8. PubMed ID: 21258248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.
    Sevko A; Sade-Feldman M; Kanterman J; Michels T; Falk CS; Umansky L; Ramacher M; Kato M; Schadendorf D; Baniyash M; Umansky V
    J Invest Dermatol; 2013 Jun; 133(6):1610-9. PubMed ID: 23223128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclophosphamide treatment induces rejection of established P815 mastocytoma by enhancing CD4 priming and intratumoral infiltration of P1E/H-2K(d) -specific CD8+ T cells.
    Rahir G; Wathelet N; Hanoteau A; Henin C; Oldenhove G; Galuppo A; Lanaya H; Colau D; Mackay CR; Van den Eynde B; Moser M
    Int J Cancer; 2014 Jun; 134(12):2841-52. PubMed ID: 24249003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-Specific Regulatory T Cells from the Bone Marrow Orchestrate Antitumor Immunity in Breast Cancer.
    Ge Y; Böhm HH; Rathinasamy A; Xydia M; Hu X; Pincha M; Umansky L; Breyer C; Hillier M; Bonertz A; Sevko A; Domschke C; Schuetz F; Frebel H; Dettling S; Herold-Mende C; Reissfelder C; Weitz J; Umansky V; Beckhove P
    Cancer Immunol Res; 2019 Dec; 7(12):1998-2012. PubMed ID: 31672785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The CCL2/CCR2 Axis Affects Transmigration and Proliferation but Not Resistance to Chemotherapy of Acute Myeloid Leukemia Cells.
    Macanas-Pirard P; Quezada T; Navarrete L; Broekhuizen R; Leisewitz A; Nervi B; Ramírez PA
    PLoS One; 2017; 12(1):e0168888. PubMed ID: 28045930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis.
    Peters W; Scott HM; Chambers HF; Flynn JL; Charo IF; Ernst JD
    Proc Natl Acad Sci U S A; 2001 Jul; 98(14):7958-63. PubMed ID: 11438742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.
    Strauss L; Bergmann C; Szczepanski M; Gooding W; Johnson JT; Whiteside TL
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4345-54. PubMed ID: 17671115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.
    Mahne AE; Mauze S; Joyce-Shaikh B; Xia J; Bowman EP; Beebe AM; Cua DJ; Jain R
    Cancer Res; 2017 Mar; 77(5):1108-1118. PubMed ID: 28122327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Roles of CCR2 and CXCR3 in the T cell-mediated response occurring during lupus flares.
    Amoura Z; Combadiere C; Faure S; Parizot C; Miyara M; Raphaël D; Ghillani P; Debre P; Piette JC; Gorochov G
    Arthritis Rheum; 2003 Dec; 48(12):3487-96. PubMed ID: 14673999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Macrophage and cancer cell cross-talk via CCR2 and CX3CR1 is a fundamental mechanism driving lung cancer.
    Schmall A; Al-Tamari HM; Herold S; Kampschulte M; Weigert A; Wietelmann A; Vipotnik N; Grimminger F; Seeger W; Pullamsetti SS; Savai R
    Am J Respir Crit Care Med; 2015 Feb; 191(4):437-47. PubMed ID: 25536148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Macrophages play an essential role in antigen-specific immune suppression mediated by T CD8⁺ cell-derived exosomes.
    Nazimek K; Ptak W; Nowak B; Ptak M; Askenase PW; Bryniarski K
    Immunology; 2015 Sep; 146(1):23-32. PubMed ID: 25808106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose cyclophosphamide induces specific tumor immunity with concomitant recruitment of LAMP1/CD107a-expressing CD4-positive T cells into tumor sites.
    Naito T; Baba T; Takeda K; Sasaki S; Nakamoto Y; Mukaida N
    Cancer Lett; 2015 Sep; 366(1):93-9. PubMed ID: 26116901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy.
    Ma Y; Mattarollo SR; Adjemian S; Yang H; Aymeric L; Hannani D; Portela Catani JP; Duret H; Teng MW; Kepp O; Wang Y; Sistigu A; Schultze JL; Stoll G; Galluzzi L; Zitvogel L; Smyth MJ; Kroemer G
    Cancer Res; 2014 Jan; 74(2):436-45. PubMed ID: 24302580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels.
    Zhao J; Cao Y; Lei Z; Yang Z; Zhang B; Huang B
    Cancer Res; 2010 Jun; 70(12):4850-8. PubMed ID: 20501849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T regulatory cells in cancer: recent advances and therapeutic potential.
    Elkord E; Alcantar-Orozco EM; Dovedi SJ; Tran DQ; Hawkins RE; Gilham DE
    Expert Opin Biol Ther; 2010 Nov; 10(11):1573-86. PubMed ID: 20955112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity.
    Perret R; Sierro SR; Botelho NK; Corgnac S; Donda A; Romero P
    Cancer Res; 2013 Nov; 73(22):6597-608. PubMed ID: 24048821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enrichment of Human CCR6
    Lee JJ; Kao KC; Chiu YL; Jung CJ; Liu CJ; Cheng SJ; Chang YL; Ko JY; Chia JS
    J Immunol; 2017 Jul; 199(2):467-476. PubMed ID: 28600287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.